Documented batches Public COA verification Research use only Quality standards
Primal Platform
← Back to all peptide profiles
Cyclic peptide Approval and post-marketing data Human data available

Peptide database · P-030

Linaclotide

Linaclotide; Constella; Linzess

Linaclotide is a disulfide-rich peptide used in authorised medicines for defined gastrointestinal indications.

01

Molecular profile

Molecular profile

Molecule class
Cyclic peptide
Origin
Synthetic analogue
Primary target system
Guanylatcyclase-C
Development stage
Authorised active substance
Structure note

Disulfidreiches 14-Aminosäuren-Peptid und Guanylatcyclase-C-Agonist.

02

Mechanism and signalling

Mechanism and signalling

Local guanylate-cyclase-C activation increases intracellular and luminal cGMP, affecting secretion and nociceptive signalling.

03

Scientific classification

Scientific classification

This profile maps Linaclotid to the research areas gastrointestinal. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.

Gastrointestinal signalling

Peptide-based regulation of secretion, motility and the intestinal barrier.

04

Evidence base

Approval and post-marketing data

PreclinicalEarly human dataClinical dataPhase IIPhase IIIApproval and post-marketing data

Randomised trials and regulatory assessments are available. They do not support systemic or unlicensed uses.

05

Regulatory status

Authorised in the EU/multiple markets

Authorised in the EU/multiple markets

The active substance is used in authorised medicines in multiple jurisdictions. Authorisations apply only to defined products, indications, quality standards and conditions of use.

06

Safety and use notice

No dosing or administration recommendation

The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.

07

Sources and registries

Sources and registries